Protein chip-based GLP-1 receptor assay system

Biochip Journal

Volumn 8, Issue 3, 2014, Pages 234-239

  Park, Chanwon ^a   Kang, In Cheol ^a,b  

^a Hoseo University   (South Korea)

^b Innopharmascreen Inc   (South Korea)

Author keywords

Exendin 4; GLP 1; GLP 1R; Protein protein interaction; ProteoChip

Indexed keywords

DOSE-DEPENDENT MANNER; EXENDIN-4; FLUORESCENT DYES; GLP-1; GLP-1R; PROTEIN-PROTEIN INTERACTIONS; RECEPTOR ASSAY; RECEPTOR-LIGAND INTERACTIONS;

PROTEINS;

EXENDIN 4; FLUORESCENT DYE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DNA BINDING; DRUG SCREENING; HUMAN; HUMAN CELL; LIGHT INTENSITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION ASSAY; PROTEIN IMMOBILIZATION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; VALIDATION PROCESS;

EID: 84911969802     PISSN: 19760280     EISSN: 20927843     Source Type: Journal    
DOI: 10.1007/s13206-014-8310-0     Document Type: Article

References (19)

1. Buse J.B. et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepaticbiomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther.29, 139–153 (2007).
2. Stonehouse A. et al. 3.5 years of exenatide maintained progressive weight reduction was associated with improvements in cardiovascular risk factors in patients with type 2 diabetes (T2DM). Obesity (Silver Spring): Abstract 271-P (2007).
3. Murphy K.G. & Bloom S.R. Nonpeptidic glucagonlike peptide 1 receptor agonists: A magic bullet for diabetes? PNAS104, 689–690 (2007).
4. Chen C. et al. Design and synthesis of a series of nonpeptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J. Med. Chem. 39, 4358–4360 (1996).
5. Doods H. et al. Pharmacological profile of BIBN 4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol.129, 420–423 (2000).
6. Ling A. et al. Identification of alkylidene hydrazides as glucagon receptor antagonists. J. Med. Chem.44, 3141–3149 (2001).
7. Lotte B.K. et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. PNAS104, 937–942 (2007).
8. Haoran S. et al. Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice. PLos One3, e2892 (2008).
9. Lee J.K. & Kang I.C. Analysis of Plk1-Bora interaction using a Protein Chip system. BioChip J.7, 151–155 (2013).
10. Park C. et al. Activity-based screening system for the discovery of neuraminidase inhibitors using protein chip technology. BioChip J.6, 133–138 (2012).
11. Park C. et al. Analysis of PKC β-mediated tyrosinase phosphorylation using ProteoChip. BioChip J.6, 392–396 (2012).
12. Park C. et al. ProteoChip-based screening system of novel inhibitors against the interaction of VEGF165 and β-Amyloid1-42. BioChip J.5, 299–303 (2011).
13. Bang J.Y. et al. Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip. BioChip J.4, 350–355 (2010).
14. Bang J.Y. et al. Anti-angiogenic effects of the water extract of HangAmDan (WEHAD), a Korean traditional medicine. SCIENCE CHINA Life Sciences54, 248–254 (2011).
15. Bang J.Y. et al. Pharmacoproteomic Analysis of a Novel Cell-permeable Peptide Inhibitor of Tumorinduced Angiogenesis. Molecular & Cellular Proteomics 10.8, M110.005264-1-M110.005264-11 (2001).
16. Kim E.Y. et al. Protein Chip-based Dipeptidyl Peptidase IV Assay System. BioChip J.3, 249–253 (2009).
17. Kang D.K. et al. Analysis of Antigen-antibody Interactions Using Combination of Protein Nanoarray and Atomic Force Measurement. BioChip J.3, 339–343 (2009).
18. Kim E.Y. et al. Erkitinib, a novel EGFR tyrosine kinase inhibitor screened using a ProteoChip system from a phytochemical library. Biochemical and Biophysical Research Communications389, 415–419 (2009).
19. Choi Y. et al. Site-specific inhibition of integrin avb3- vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin. Proteomics10, 72–80 (2010).